丁香园AV

The European Commission and the Canadian Institutes of Health Research have announced more than $12 million in funding to expand 丁香园AV鈥檚 iReceptor initiative.

iReceptor is a newly developed platform for managing massive repositories of worldwide distributed data that researchers can securely access in their quest to develop new therapies for autoimmune and infectious diseases, and cancer.

Felix Breden, iReceptor鈥檚 scientific director and a professor of biological sciences, says the undertaking is a prime example of how integrating data across multiple studies and institutions is critical to health research.

鈥淭hink of it as an enormous data repository that holds the millions of patterns of responses that the immune system uses to fight disease and infection,鈥� he says.

Breden says many cutting-edge therapies rely on manipulating the immune system so that it triggers the body鈥檚 ability to recognize and remove cancer cells and infectious pathogens.

Yet figuring out what these patterns are and how to engage or disengage them is a staggering proposition.

Now, however, for the first time, researchers around the world will be able to share and analyze huge datasets, taken from healthy and unhealthy patients, that have been sequenced and stored through iReceptor.

So far, researchers using the iReceptor Gateway can access more than 700 million sequences of AIRR-seq (Adaptive Immune Receptor Repertoire) data amassed in multiple world-wide repositories. With the new funding, iReceptor will expand to include repositories from France, Germany, Norway, Israel, India and many other countries, as well as data repositories at biopharma and biotech companies, hospitals and clinics.

iReceptor鈥檚 ability to securely offer data as well as metadata (such as gender, ethnicity, treatment and outcome) ensures patient privacy while allowing researchers to understand which conditions activate or suppress various immune-system genes.

Collaborator Sachdev Sidhu, at the University of Toronto鈥檚 Donnelly Centre, is looking forward to using iReceptor in his research.

鈥淭he iReceptor initiative will be highly useful in our efforts to design new antibodies for the treatment of cancer and other diseases,鈥� says Sidhu. 鈥淚t will enable us to obtain information about natural antibodies that we can apply to the design of synthetic antibodies that can be used as drugs.鈥�

Breden notes that, when fully developed, iReceptor will be revolutionary.

鈥淣ot only will we have a better understanding of the causes of infectious and autoimmune disease and cancer, but we hope this will lead to early detection, new therapies and improved patient care around the world,鈥� he says.

鈥淭his is great news, not just for 丁香园AV and Felix Breden鈥檚 team, but for immunotherapy researchers at large,鈥� says 丁香园AV鈥檚 Associate Vice-President, Research, Dugan O鈥橬eil.

鈥淲ith this award from CIHR, in tandem with the European Commission award, the extended technical work on iReceptor will improve secure data-sharing and repository scaling, as well as expansion into the use of advanced algorithms and single cell data integration. We congratulate everyone involved in this collaborative project between European and Canadian researchers, and thank the funders for their support of the project.鈥�

The funding will support iReceptor鈥檚 managing team of computer scientists, data curators, bioinformaticists and scientists at 丁香园AV who played a key role in developing the project.